Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Triple Negative Breast Neoplasms 2Breast Neoplasms 2Hodgkin Disease 1Hematopoietic and Lymphatic System Neoplasm 1Graft vs Host Disease 1Cholangiocarcinoma 1Bronchiolitis Obliterans Syndrome 1

Interventions

ibrutinib 3ruxolitinib 2asciminib 2Alemtuzumab 2sodium luminolate 1posaconazole 1ponatinib 1pegfilgrastim 1ofatumumab 1nilotinib 1montelukast 1mocetinostat 1lonafarnib 1ixekizumab 1fludarabine 1bosutinib 1belumosudil 1baricitinib 1axatilimab 1Voriconazole 1Tomography, X-Ray Computed 1Sofosbuvir 1Saline Solution 1SLC25A33 protein, human 1Rituximab 1Ribavirin 1Respiratory Function Tests 1Prednisone 1Pentostatin 1Oxycodone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Bronchiolitis Obliterans Syndrome × axatilimab × Clear all
NCT04710576 2026-03-16

AGAVE-201

Syndax Pharmaceuticals

Phase 2 Active not recruiting
241 enrolled 11 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡